vorinostat has been researched along with Cell Transformation, Neoplastic in 10 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Cell Transformation, Neoplastic: Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with Vorinostat/JQ1 inhibited glycolysis/MTOR signaling, activated the clock, and upregulated the UPR and autophagy via inhibition of YAP1/NF-κB." | 1.48 | YAP1 enhances NF-κB-dependent and independent effects on clock-mediated unfolded protein responses and autophagy in sarcoma. ( Babichev, Y; C Brady, D; Chor, S; E Ciotti, G; E Marino, G; Egolf, S; Eisinger-Mathason, TSK; Gladdy, R; Koumenis, C; Leli, NM; Liu, Y; Mancuso, A; Pak, K; Park, PMC; Posimo, JM; Qi, J; Rivera-Reyes, A; Sostre-Colón, J; Tameire, F; Weber, K; Ye, S, 2018) |
| "DER significantly reduced mammary cancer incidence, multiplicity, and cancer burden and prolonged cancer latency (P < 0." | 1.39 | Defining the role of histone deacetylases in the inhibition of mammary carcinogenesis by dietary energy restriction (DER): effects of suberoylanilide hydroxamic acid (SAHA) and DER in a rat model. ( Jiang, W; McGinley, JN; Thompson, HJ; Zhu, Z, 2013) |
| " The present results show the applicability of our novel statistical methodology for quantitatively assessing drug synergy across a wide range of doses of agents with complex dose-response profiles, a methodology with great potential for advancing the development of chemopreventive combinations." | 1.36 | Validation of a novel statistical model for assessing the synergy of combined-agent cancer chemoprevention. ( Fujimoto, J; Hong, WK; Kong, M; Lee, JJ; Lotan, R, 2010) |
| "HDACis are a group of novel anticancer agents." | 1.34 | Histone deacetylase inhibitors selectively suppress expression of HDAC7. ( Clarke, C; Dokmanovic, M; Marks, PA; Ngo, L; Parmigiani, RB; Perez, G; Xu, W, 2007) |
| "Murine erythroleukemia cells developed for resistance to SAHA are cross-resistant to trichostatin A, a known deacetylase inhibitor and differentiation inducer, but are not cross-resistant to HMBA." | 1.30 | A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. ( Breslow, R; Emiliani, S; Marks, PA; Richon, VM; Rifkind, RA; Verdin, E; Webb, Y, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chhabra, R | 1 |
| Rockfield, S | 1 |
| Guergues, J | 1 |
| Nadeau, OW | 1 |
| Hill, R | 1 |
| Stevens, SM | 1 |
| Nanjundan, M | 1 |
| Ye, S | 2 |
| Lawlor, MA | 1 |
| Rivera-Reyes, A | 2 |
| Egolf, S | 2 |
| Chor, S | 2 |
| Pak, K | 2 |
| Ciotti, GE | 1 |
| Lee, AC | 1 |
| Marino, GE | 1 |
| Shah, J | 1 |
| Niedzwicki, D | 1 |
| Weber, K | 2 |
| Park, PMC | 2 |
| Alam, MZ | 1 |
| Grazioli, A | 1 |
| Haldar, M | 1 |
| Xu, M | 1 |
| Perry, JA | 1 |
| Qi, J | 2 |
| Eisinger-Mathason, TSK | 2 |
| E Marino, G | 1 |
| E Ciotti, G | 1 |
| Liu, Y | 1 |
| Posimo, JM | 1 |
| Babichev, Y | 1 |
| Sostre-Colón, J | 1 |
| Tameire, F | 1 |
| Leli, NM | 1 |
| Koumenis, C | 1 |
| C Brady, D | 1 |
| Mancuso, A | 1 |
| Gladdy, R | 1 |
| Ge, Y | 1 |
| Gong, Z | 1 |
| Olson, JR | 1 |
| Xu, P | 1 |
| Buck, MJ | 1 |
| Ren, X | 1 |
| Fujimoto, J | 1 |
| Kong, M | 1 |
| Lee, JJ | 1 |
| Hong, WK | 1 |
| Lotan, R | 1 |
| Xu, S | 1 |
| De Becker, A | 1 |
| De Raeve, H | 1 |
| Van Camp, B | 1 |
| Vanderkerken, K | 1 |
| Van Riet, I | 1 |
| Zhu, Z | 1 |
| Jiang, W | 1 |
| McGinley, JN | 1 |
| Thompson, HJ | 1 |
| Ogawa, T | 1 |
| Hayashi, T | 1 |
| Tokunou, M | 1 |
| Nakachi, K | 1 |
| Trosko, JE | 1 |
| Chang, CC | 1 |
| Yorioka, N | 1 |
| Dokmanovic, M | 1 |
| Perez, G | 1 |
| Xu, W | 1 |
| Ngo, L | 1 |
| Clarke, C | 1 |
| Parmigiani, RB | 1 |
| Marks, PA | 2 |
| Richon, VM | 1 |
| Emiliani, S | 1 |
| Verdin, E | 1 |
| Webb, Y | 1 |
| Breslow, R | 1 |
| Rifkind, RA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| IGHID 11424 - A Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (The VOR VAX Study)[NCT02707900] | Phase 1 | 6 participants (Actual) | Interventional | 2016-03-31 | Terminated (stopped due to Manufacturing of the AGS-004 HIV vaccine by Argos could no longer be provided.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 other studies available for vorinostat and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
Global miRNA/proteomic analyses identify miRNAs at 14q32 and 3p21, which contribute to features of chronic iron-exposed fallopian tube epithelial cells.
Topics: Azacitidine; Biomarkers, Tumor; Cell Line, Transformed; Cell Transformation, Neoplastic; Down-Regula | 2021 |
YAP1-Mediated Suppression of USP31 Enhances NFκB Activity to Promote Sarcomagenesis.
Topics: Adaptor Proteins, Signal Transducing; Angiomotins; Animals; Antineoplastic Agents; Azepines; Cell Cy | 2018 |
YAP1 enhances NF-κB-dependent and independent effects on clock-mediated unfolded protein responses and autophagy in sarcoma.
Topics: Activating Transcription Factor 6; Adaptor Proteins, Signal Transducing; Animals; Autophagy; Azepine | 2018 |
Inhibition of monomethylarsonous acid (MMA(III))-induced cell malignant transformation through restoring dysregulated histone acetylation.
Topics: Acetylation; Cell Transformation, Neoplastic; Cells, Cultured; Histone Deacetylase 1; Histone Deacet | 2013 |
Validation of a novel statistical model for assessing the synergy of combined-agent cancer chemoprevention.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Cell Prol | 2010 |
In vitro expanded bone marrow-derived murine (C57Bl/KaLwRij) mesenchymal stem cells can acquire CD34 expression and induce sarcoma formation in vivo.
Topics: Animals; Antigens, CD34; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Transformation, Neoplast | 2012 |
Defining the role of histone deacetylases in the inhibition of mammary carcinogenesis by dietary energy restriction (DER): effects of suberoylanilide hydroxamic acid (SAHA) and DER in a rat model.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Caloric Restriction; Cell Transformation, Neoplast | 2013 |
Suberoylanilide hydroxamic acid enhances gap junctional intercellular communication via acetylation of histone containing connexin 43 gene locus.
Topics: Acetylation; Animals; Apoptosis; Cell Communication; Cell Growth Processes; Cell Transformation, Neo | 2005 |
Histone deacetylase inhibitors selectively suppress expression of HDAC7.
Topics: Acetylation; Blotting, Northern; Blotting, Western; Cell Transformation, Neoplastic; Cyclin-Dependen | 2007 |
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.
Topics: Acetamides; Animals; Carcinoma; Cell Differentiation; Cell Line, Transformed; Cell Transformation, N | 1998 |